AREDS 2 formula products hit market

Madison, NJ-A new eye vitamin and mineral supplement was introduced by Bausch + Lomb at the 2013 American Society of Retina Specialists annual meeting.

The patented formula, PreserVision AREDS 2, matches the updated equation based on the latest clinical evidence from the National Eye Institute (NEI) Age-Related Eye Disease Study 2 (AREDS 2).

“When recommending an AREDS supplement, doctors want to be sure that they are selecting a formula that is appropriate for their patient and supported by the latest scientific evidence,” said Michael J. Cooney, MD, MBA, retina specialist, Vitreous Retina Macula Consultants, New York. “Having this new formula . . . simplifies that decision.”

The daily dose-two soft gels-of the formula provides the same levels of all six clinically proven nutrients as the NEI-supported equation: vitamin C (500 mg), vitamin E (400 IU), lutein (10 mg)/zeaxanthin (2 mg), zinc (80 mg zinc oxide), and copper (2 mg cupric oxide).

“As the leader in ocular nutrition, Bausch + Lomb is committed to providing the most current, science-based eye vitamin formulations,” said Calvin Roberts, MD, chief medical officer, ophthalmology and eye health, Bausch + Lomb. “We are proud to be able to offer this updated . . . formulation that exactly matches NEI-supported formula so soon after the study results were announced.”

The new formula will soon be available in the United States.

In related news, Macular Health’s Visual Advantage has also released a new product that features the AREDS 2 formula.

“Since 2003, our company has utilized the latest medical technology to engineer the finest pharmaceutical grade supplements available at the most affordable prices to the consumer,” said Jeffery McAnnally, Macular Heath chief executive officer. “We consider our product more than just a vitamin, we are our customers’ vision.”

The supplement is now available. For more information, go to www.macularhealth.com.

For more articles in this issue of Ophthalmology Times eReport, click here.

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.